Publication: Fibrolytic vaccination against ADAM12 reduces desmoplasia in preclinical pancreatic adenocarcinomas
Fibrolytic vaccination against ADAM12 reduces desmoplasia in preclinical pancreatic adenocarcinomas
Date
Date
Date
Citations
Chen, J., Sobecki, M., Krzywinska, E., Thierry, K., Masmoudi, M., Nagarajan, S., Fan, Z., He, J., Ferapontova, I., Nelius, E., Seehusen, F., Gotthardt, D., Takeda, N., Sommer, L., Sexl, V., Münz, C., DeNardo, D., Hennino, A., & Stockmann, C. (2024). Fibrolytic vaccination against ADAM12 reduces desmoplasia in preclinical pancreatic adenocarcinomas. EMBO Molecular Medicine, 16(12), 3033–3056. https://doi.org/10.1038/s44321-024-00157-4
Abstract
Abstract
Abstract
A hallmark feature of pancreatic ductal adenocarcinoma (PDAC) is massive intratumoral fibrosis, designated as desmoplasia. Desmoplasia is characterized by the expansion of cancer-associated fibroblasts (CAFs) and a massive increase in extracellular matrix (ECM). During fibrogenesis, distinct genes become reactivated specifically in fibroblasts, e.g., the disintegrin metalloprotease, ADAM12. Previous studies have shown that immunotherapeutic ablation of ADAM12$^{+}$
Additional indexing
Creators (Authors)
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Page end
Page end
Page end
Item Type
Item Type
Item Type
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Citations
Chen, J., Sobecki, M., Krzywinska, E., Thierry, K., Masmoudi, M., Nagarajan, S., Fan, Z., He, J., Ferapontova, I., Nelius, E., Seehusen, F., Gotthardt, D., Takeda, N., Sommer, L., Sexl, V., Münz, C., DeNardo, D., Hennino, A., & Stockmann, C. (2024). Fibrolytic vaccination against ADAM12 reduces desmoplasia in preclinical pancreatic adenocarcinomas. EMBO Molecular Medicine, 16(12), 3033–3056. https://doi.org/10.1038/s44321-024-00157-4